Loading clinical trials...

Screening for Advanced Heart Failure Treatment (SEE-HF) | Clinical Trials | Clareo Health

COMPLETED

Screening for Advanced Heart Failure Treatment (SEE-HF)

NCT01626404•Abbott Medical Devices

Summary

Advanced heart failure therapy (heart transplantation or LVAD) is underutilized and patients are underserved. The purpose of this prospective, observational study is to obtain multi-center data on the proportion of patients with CRT and/or ICD who are candidates for advanced heart failure treatment and obtain insights into patient and physician decisions regarding referral for advanced heart failure therapy.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•CRT and or ICD device in place.
•NYHA class III - IV heart failure
•EF \</= 40%
•Patient is an out-patient
•Patient is on optimal medical management as tolerated and as defined by primary care physician.
•Patient has signed an informed consent for data collection.

Exclusion Criteria

•Age \<18 years or \>80 years
•CRT device that has been implanted \< 3 months prior to enrollment
•Coronary revascularization within 3 months prior to enrollment
•Patient only has ICD but has CRT planned
•Non-cardiac disease resulting in life expectancy \< 2 yrs
•Patient is hospitalized or will be hospitalized at this time
•Known diagnosis of dementia
•Patient is currently on dialysis
•Oxygen dependent lung disease
•Previously or currently treated with LVAD or heart transplantation

Locations (7)

Rigshospitalet

Copenhagen, Denmark

CHU of Nantes

Nantes, France

Hannover Medical Center

Hanover, Germany

University Clinical Center Tuebingen

Tübingen, Germany

Erasmus Medical Center

Rotterdam, Netherlands

Karolinska University Hospital

Stockholm, Sweden

University Hospital of South Manchester NHS Trust

Manchester, United Kingdom

Key Dates

Start Date

October 1, 2012

Primary Completion Date

February 1, 2016

Completion Date

February 1, 2016

Last Updated

June 24, 2022

Enrollment

ACTUAL participants

Conditions

Advanced Heart FailureCRT and/or ICD

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

NCT06228209

Advanced Heart FailureAdvanced Non-colorectal Gastro-intestinal Cancer+1 more

View study

ACTIVE_NOT_RECRUITINGNA

Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

NCT04475393

Advanced Heart Failure

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Screening for Advanced Heart Failure Treatment (SEE-HF)

Inclusion Criteria

Exclusion Criteria

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients

Evaluation of Electrical and Hemodynamic Effects of Different Pacing Strategies in CRT Candidates

Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea

Hong Kong and Taiwan HM3 PMS